MARKET

CMMB

CMMB

Chemomab Therapeutics Ltd
NASDAQ
0.6790
+0.0191
+2.89%
Opening 13:05 04/23 EDT
OPEN
0.6440
PREV CLOSE
0.6599
HIGH
0.6799
LOW
0.6440
VOLUME
2.68K
TURNOVER
0
52 WEEK HIGH
1.890
52 WEEK LOW
0.4200
MARKET CAP
9.65M
P/E (TTM)
-0.0165
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CMMB last week (0415-0419)?
Weekly Report · 1d ago
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Barchart · 5d ago
Weekly Report: what happened at CMMB last week (0408-0412)?
Weekly Report · 04/15 11:26
Weekly Report: what happened at CMMB last week (0401-0405)?
Weekly Report · 04/08 11:30
Weekly Report: what happened at CMMB last week (0325-0329)?
Weekly Report · 04/01 11:28
Weekly Report: what happened at CMMB last week (0318-0322)?
Weekly Report · 03/25 11:31
Chemomab Bagged New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab's CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis. The European Patent Office has granted a new patent for the drug. Chemomab is developing a first-in-class antibody that neutralizes CCL24.
Benzinga · 03/25 11:09
Weekly Report: what happened at CMMB last week (0311-0315)?
Weekly Report · 03/18 11:29
More
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Webull offers Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ: CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.